| Autor: |
A, Tursi, G, Mocci, A, Cuomo, L, Allegretta, G, Aragona, R, Colucci, N, Della Valle, A, Ferronato, G, Forti, F, Gaiani, M G, Graziani, R, Lorenzetti, F, Luzza, P, Paese, A, Penna, R, Pica, S, Piergallini, G, Pranzo, S, Rodino, A, Scarcelli, C, Zampaletta, C, Cicerone, A, Cocco, G, De' Angelis, L, Donnarumma, M, Franceschi, S, Gallina, G, Grasso, T, Larussa, I, Luppino, R, Faggiani, L, Fanigliulo, C, Pagnini, P, Perazzo, R, Sacco, L, Sebkova, S, Scorza, M, Serio, A, De Monti, M, Picchio, W, Elisei, G, Maconi |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
European review for medical and pharmacological sciences. 25(4) |
| ISSN: |
2284-0729 |
| Popis: |
Ustekinumab (UST) is an anti-IL12/23 antibody for the treatment of Crohn's Disease (CD). The aim of this study was to compare the efficacy and safety of UST in a large population-based cohort of CD patients who failed previous treatment with other biologics.194 CD patients (108 males and 86 females, mean age 48 years (range 38-58 years) were retrospectively reviewed. 147 patients were already treated with anti-TNFα (75.8%), and 47 (24.2%) patients were already treated with anti-TNFα and vedolizumab. Concomitant treatment with steroids was present in 177 (91.2%) patients.At week 12, clinical remission was achieved in 146 (75.2%) patients. After a mean follow-up of 6 months, clinical remission was maintained in 135 (69.6%) patients; at that time, mucosal healing was assessed in 62 (31.9%) patients, and it was achieved in 33 (53.2) patients. Three (1.5%) patients were submitted to surgery. Steroid-free remission was achieved in 115 (59.3%) patients. Both serum C-Reactive Protein and Fecal Calprotectin (FC) levels were significantly reduced with respect to baseline levels during follow-up. A logistic regression, UST therapy as third-line therapy (after both anti-TNFα and vedolizumab), FC200 µg/g, and HBI ≥8 were significantly associated with lack of remission. Adverse events occurred in 5 (2.6%) patients, and four of them required suspension of treatment.UST seemed to be really effective and safe in CD patients unresponsive to other biologic treatments, especially when used as second-line treatment. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
